Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MerLion Preps Finafloxacin For Phase III As Advantages Confirmed

This article was originally published in PharmAsia News

Executive Summary

Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.

You may also be interested in...



Biogen’s Tau Antibody Fails In PSP, But Alzheimer’s Studies Continue

Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing. 

Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied

Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m. 

Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types

RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089189

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel